Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Sabry M Attia; Mohammed A Al-Hamamah; Moureq R Alotaibi; Abdullah F Alasmari; Mohamed S M Attia; Sheikh F Ahmad; Mohamed A Mahmoud; Ahmed Nadeem; Mushtaq A Ansari; Saleh A Bakheet

doi:10.1016/j.mrgentox.2023.503635

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Mutat Res Genet Toxicol Environ Mutagen. 2023 May-Jun:888:503635. doi: 10.1016/j.mrgentox.2023.503635. Epub 2023 Apr 3.

Affiliations

¹ Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. Electronic address: attiasm@ksu.edu.sa.
² Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

PMID: 37188433
DOI: 10.1016/j.mrgentox.2023.503635

Abstract

Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

Keywords: 8-OHdG; Aneugenicity; Anti-CD20; Clastogenicity; Inflammation; Oxidative DNA damage.

MeSH terms

Aneugens*
Animals
Arthritis, Rheumatoid* / drug therapy
Disease Models, Animal
In Situ Hybridization, Fluorescence
Mice
Mice, Inbred DBA
Mutagens
Rituximab / pharmacology

Substances

Rituximab
Aneugens
Mutagens